Marka Crittenden

Radiology / Radiation Oncology

Credentials: · · · ·

History

(PQ11) Targeting STING in the Context of Chemoradiation Therapy to Overcome Poor Preexisting Immunity in Mouse Models of Pancreatic Cancer.
National Cancer Institute · R01
Contact PI · $1.9M · Providence Portland Medical Center
2016–2021
Increasing the Potency of Listeria Monocytogenes-Based Vaccines by Eliminating Vaccine-Related Gamma Delta T Cell Responses.
National Institute of Allergy and Infectious Diseases · R21
Contact PI · $453.8K · Providence Portland Medical Center
2016–2019
Generation of a Novel Fusion Protein to Redirect Macrophage Differentiation Following Radiation Therapy.
National Cancer Institute · R03
Contact PI · $165K · Providence Portland Medical Center
2015–2018
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma
National Cancer Institute · R21
Contact PI · $349.3K · Providence Portland Medical Center
2013–2016

Immunoscore in Rectal Cancer
Principal investigator · Completed
Providence Health & Services
2014–2018
Phase I Study of Safety and Immunogenicity of ADU-623
Principal investigator · Completed · Phase 1
Providence Health & Services
2014–2018
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
Principal investigator · Completed · Phase 1
Providence Health & Services
2012–2018
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Principal investigator · Active not recruiting · Phase 2
Providence Health & Services
2011–2026